Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.

Joyce F LiuNiya XiongSusana M CamposAlexi A WrightCarolyn KrasnerSusan SchumerNeil HorowitzJennifer VenerisNabihah TayobStephanie MorrisseyGabriela WestRoxanne QuinnUrsula A MatulonisPanagiotis A Konstantinopoulos

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

Adavosertib monotherapy demonstrated encouraging and durable evidence of activity in women with USC, and further investigation of this agent in this cancer and biomarkers of activity are indicated.

Keyphrases

phase ii study
open label
high grade
papillary thyroid
locally advanced
squamous cell
randomized controlled trial
combination therapy
squamous cell carcinoma
radiation therapy
study protocol
childhood cancer